IP Library Granted Patent US 10,179,900
Granted Patent B2
US 10,179,900 · App. 12/339,872 · Granted Jan 15, 2019

Conditioned media and methods of making a conditioned media

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,179,900
App. No.
12/339,872
Granted
Jan 15, 2019
Kind
B2
Abstract

A stable and scalable process is provided to manufacture reduced serum umbilical cord tissue-derived (UTC)-conditioned media. The method includes the culture of a UTC under reduced serum conditions. Subsequently, the UTC is washed and grown in serum-free basal media. After approximately 24 hours, the conditioned media is collected, filtered and concentrated by use of an approximately 5 kDa or similar cut-off membrane.

Claims (55)

1. A method of preparing a conditioned media, the method comprising:

providing an isolated human umbilical tissue-derived cell (UTC) in a serum-containing microcarrier bead culture media in a spinner flask;

reducing serum content of the culture media in one or more incremental steps;

transferring the UTC from the reduced serum content culture media to a serum-free basal media when the serum content reaches a predetermined level;

growing the UTC in the serum-free basal media for no more than 24 hours; and

isolating the UTC from the serum-free basal media leaving a conditioned media, wherein serum proteins are undetectable in the conditioned media using SDS-PAGE in a 4-20% tris-glycine gel.

2. The method of claim 1 , further comprising filtering the conditioned media.

3. The method of claim 1 , further comprising concentrating the conditioned media.

4. The method of claim 1 , wherein the human umbilical tissue-derived cell is positive for CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, HLA-A, B, C and negative for CD31, CD34, CD45, CD117, CD141 and HLA-DR, DP, DQ.

5. The method of claim 1 , wherein the microcarrier in the microcarrier bead culture media is polystyrene modified with cationic amine.

6. A method of preparing a conditioned media, the method comprising:

seeding a human umbilical cord tissue-derived cell (UTC) in a serum-containing microcarrier bead culture media in a spinner flask;

reducing serum content of the culture media in one or more incremental steps;

transferring the UTC from the reduced serum-content culture media to a serum-free basal media;

growing the UTC in the serum-free basal media for no more than 24 hours; and

isolating the UTC from the serum-free basal media leaving a conditioned media, wherein serum proteins are undetectable in the conditioned media using SDS-PAGE in a 4-20% tris-glycine gel;

wherein the protein content in the conditioned media is at least about two times more than from a static flask.

7. The method of claim 6 , wherein the conditioned media is filtered.

8. The method of claim 7 , wherein the conditioned media is filtered using an approximately 0.22 micron filter.

9. The method of claim 6 , wherein the conditioned media is concentrated.

10. The method of claim 9 , wherein the conditioned media is concentrated with a cut-off membrane.

11. The method of claim 10 , wherein the cut-off membrane is an approximately 5 kDa cut-off membrane.

12. The method of claim 6 , wherein the serum content is reduced in increments of about 5% to about 60%.

13. The method of claim 6 , wherein the serum content is reduced in increments of about 50%.

14. The method of claim 6 , wherein the UTC grows for about 1 to 3 passages in each increment.

15. The method of claim 14 , wherein the UTC grows for about 2 passages in each increment.

16. The method of claim 6 , further comprising preliminarily culturing the UTC in a standard culture media and isolating the UTC from the standard culture media before seeding.

17. The method of claim 6 , wherein the human umbilical tissue-derived cell is positive for CD10, CD13, CD44, CD73, CD90, PDGFr-alpha, HLA-A, B, C and negative for CD31, CD34, CD45, CD117, CD141 and HLA-DR, DP, DQ.

18. The method of claim 6 , wherein the microcarrier in the microcarrier bead culture media is polystyrene modified with cationic amine.

19. A method of preparing a conditioned media, the method comprising:

seeding a human umbilical cord tissue-derived cell (UTC) in a serum-containing microcarrier bead culture media in a spinner flask;

reducing serum content of the culture media in one or more incremental steps;

transferring the UTC from the reduced serum-content culture media to a serum-free basal media;

growing the UTC in the serum-free basal media for up to about 24 hours; and

isolating the UTC from the serum-free basal media leaving a conditioned media, wherein serum proteins are undetectable in the conditioned media using Western blot analysis, wherein the Western Blot analysis comprises protein separation in a 4-20% tris-glycine gel and a mouse monoclonal anti-BSA antibody.

20. The method of claim 19 , wherein the conditioned media is filtered.

21. The method of claim 20 , wherein the conditioned media is filtered using an approximately 0.22 micron filter.

22. The method of claim 19 , wherein the conditioned media is concentrated.

23. The method of claim 22 , wherein the conditioned media is concentrated with a cut-off membrane.

24. The method of claim 23 , wherein the cut-off membrane is an approximately 5 kDa cut-off membrane.

25. The method of claim 19 , wherein the serum content is reduced in increments of about 5% to about 60%.

26. The method of claim 19 , wherein the serum content is reduced in increments of about 50%.

27. The method of claim 19 , wherein the UTC grows for about 1 to 3 passages in each increment.

28. The method of claim 27 , wherein the UTC grows for about 2 passages in each increment.

29. The method of claim 19 , further comprising preliminarily culturing the UTC in a standard culture media and isolating the UTC from the standard culture media before seeding.

30. The method of claim 19 , wherein the microcarrier in the microcarrier bead culture media is polystyrene modified with cationic amine.

31. A method of preparing a conditioned media, the method comprising:

providing an isolated human umbilical tissue-derived cell (UTC) in a serum-containing microcarrier bead culture media in a spinner flask;

reducing serum content of the culture media in one or more incremental steps;

transferring the UTC from the reduced serum content culture media to a serum-free basal media when the serum content reaches a predetermined level;

growing the UTC in the serum-free basal media for no more than 24 hours; and

isolating the UTC from the serum-free basal media leaving a conditioned media, wherein serum proteins are undetectable in the conditioned media using Western blot analysis, wherein the Western Blot analysis comprises protein separation in a 4-20% tris-glycine gel and a mouse monoclonal anti-BSA antibody.

32. The method of claim 31 , further comprising filtering the conditioned media.

33. The method of claim 31 , further comprising concentrating the conditioned media.

34. The method of claim 31 , wherein the microcarrier in the microcarrier bead culture media is polystyrene modified with cationic amine.

Assignments (8)
CHANGE OF NAME Recorded Sep 23, 2016
From: DEPUY SYNTHES PRODUCTS, LLC
To: DEPUY SYNTHES PRODUCTS, INC.
Reel/Frame 040127/0008 →
CHANGE OF NAME Recorded Sep 23, 2016
From: DEPUY SPINE, INC.
To: DEPUY SPINE, LLC
Reel/Frame 040132/0609 →
CHANGE OF NAME Recorded Sep 23, 2016
From: HAND INNOVATIONS, LLC
To: DEPUY SYNTHES PRODUCTS, LLC
Reel/Frame 040132/0644 →
MERGER Recorded Sep 23, 2016
From: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
To: DEPUY ORTHOPAEDICS, INC.
Reel/Frame 039841/0395 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2016
From: DEPUY ORTHOPAEDICS, INC.
To: DEPUY SPINE, INC.
Reel/Frame 039841/0414 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 23, 2016
From: DEPUY SPINE, LLC
To: HAND INNOVATIONS, LLC
Reel/Frame 039841/0449 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2011
From: ETHICON, INCORPORATED
To: ADVANCED TECHNOLOGIES AND REGENERATIVE MEDICINE, LLC
Reel/Frame 026291/0076 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2009
From: HARMON, ALEXANDER M.; ANG, ABEL
To: ETHICON, INCORPORATED
Reel/Frame 022374/0213 →
Cited By (2)
US 12,347,100 US 12,508,349